EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 556 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera March 28, 2024 Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto June 18, 2020 ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A... November 12, 2025 ESMO Breast Cancer Congress 2023 April 17, 2023 Load more HOT NEWS EMA Recommends Extension of Indications for Idecabtagene Vicleucel Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... How to Be Brave When Your Parent Has Cancer: A Kid’s... EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria
